• Neuro-oncology drug developer CNS Pharmaceuticals is completing an underwritten public offering of common stock shares and warrants in a bid to fund its upcoming Phase 2 trials for a candidate in fighting glioblastoma brain cancers
• CNS’s Phase 2 trials are scheduled to begin during Q1 of 2021, building on a Phase 1 trial in which 44 percent of patients saw improvement and one patient has survived cancer-free for nearly 15 years
• The company has designed an ambitious, adaptive trial that allows for an interim analysis of data and adjustments for efficiency in bringing the drug candidate, Berubicin, to hoped-for approval as a glioblastoma treatment
• CNS is aiming for FDA approval of an expedited development pathway to obtain maximum efficiency in its timeline
• A recent syndicated broadcast provided CNS with additional publicity, shining a spotlight on its achievements in obtaining FDA approval for Investigational New Drug (“IND”) status

The dawning of a new year is traditionally a time when people embrace the hope of new promise in defeating the disappointments of the past months, and the advent of 2021’s calendar is perhaps more so than ever as a growing number of vaccines against the worldwide COVID-19 pandemic begin to roll out to the public in tiered priority phases. Also just over the new year’s horizon is the launch of Phase 2 testing by neuro-oncology biopharmaceutical company CNS Pharmaceuticals (NASDAQ: CNSP) as CNS advances an ambitious agenda for developing a drug candidate that has shown promise in the fight against glioblastoma, a deadly brain cancer that has no known cure or longevity-building treatment. CNS’s drug candidate Berubicin was the focus of another company’s Phase 1 safety trials nearly 15 years ago. Out of 25 trial participants in the 2006 analysis, 11 of them (44 percent) achieved “statistically significant improvement in clinical benefit” and one of them continued to survive completely cancer-free as of last Feb. 20, when the most recent patient evaluation was conducted. Since glioblastoma patients have a median survival rate of only 14.6 months from the date of the malignancy’s diagnosis, the patient’s response has excited interest in Berubicin’s potential (https://ibn.fm/8wVG3). CNS recently conducted an underwritten public offering of 5 million shares of common stock as well as warrants to purchase up to 2.5 million shares of common stock, selling the stocks and warrants together at a combined public offering price of $2 per share and warrant to fund the upcoming Phase 2 trial as well as other research and development. CNS also granted the underwriter a 45-day option to purchase up to an additional 750,000 shares of common stock and/or 375,000 warrants to cover over-allotments, if any occur. The offering was expected to close on or about Dec. 28 (https://ibn.fm/4j2B5). “Anthracyclines as a class of chemotherapy have been used for over 60 years to treat a variety of cancers. … However, historically, anthracyclines have never been used to treat primary or metastatic brain cancers because scientists could not demonstrate that anthracyclines were able to cross the blood-brain barrier and achieve significant levels of activity in the brain,” CEO John Climaco said during a recent webinar (https://ibn.fm/c1d6K). “Berubicin may change that history because it is the first anthracycline that, based on limited clinical data, appears to cross the blood-brain barrier and achieve drug levels critical for efficacy against central nervous system malignancies.” The U.S. Food and Drug Administration (“FDA”) approved CNS’s Investigational New Drug (“IND”) application for Berubicin shortly before Christmas, and the company’s success in that endeavor was highlighted in a recent broadcast via NetworkNewsAudio (“NNA”) to thousands of syndication points (https://ibn.fm/F8N5C). “Since becoming a public company, our clear focus has been on advancing the clinical development of Berubicin. We will now rapidly move to initiate our Phase 2 trial of Berubicin for adults with GBM and expect to begin enrolling patients in the first quarter of next year,” Climaco stated in a news release about the broadcast. “The Company will transform within the next several months as Berubicin becomes the subject of up to three active clinical trials, which include our randomized, controlled Phase 2 trial in the U.S., and 2 trials planned by our sublicensee WPD in Poland.” The trial’s adaptive, stage-progressive design is intended to allow an interim analysis of the data for efficacy and then to allow an adjustment in patient population if necessary to make the most efficient and rapid use of time. CNS anticipates its trial strategy may potentially grant it an expedited pathway for development with the FDA if it continues to be successful. For more information, visit the company’s website at www.CNSPharma.com NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

• Frank D. Heuszel, Sassuan (Sam) Lee are DSS board members; will serve as SHRG directors
• New board members focused on helping SHRG continue to develop products and markets, grow independent sales force, build shareholder value
• DSS owns 37% of the outstanding shares of Sharing Services

Sharing Services Global (OTCQB: SHRG), a diversified holding company specializing in the health and wellness direct-selling industry, has announced two new board members. The new members — Frank D. Heuszel and Sassuan (Sam) Lee — will serve as directors and are Document Security Systems Inc. (“DSS”) board members (https://ibn.fm/TG7h2). DSS owns 37% of the outstanding shares of Sharing Services. “I look forward to being part of the team to help grow Sharing Services and to build upon the success that their team and the other Sharing Services Directors have already achieved. I am excited about helping Sharing Services continue to serve its customers, develop new products and markets, to grow its independent representative network, and to build shareholder value,” said Heuszel, CEO of DSS. Heuszel is a practicing attorney, a certified public accountant, and a certified internal auditor. He has almost 40 years of experience in accounting and finance matters. Mr. Heuszel’s law practice focuses on the regulation and operation of banks, corporate restructures, and mergers and acquisitions. “The success that this company has achieved thus far is amazing, and I hope to bring my expertise and international business experience to the Board and continue to add value,” said Lee, a prominent entrepreneur and finTech executive. Lee has more than 20 years’ experience in the TMET sector, with substantial success in commercializing various blockchain, digital and e-business projects. His vision is to bring wealth inclusion and improve economic inequality in the world by diminishing the boundaries among nations and connecting isolated economies through financial technology and innovation. DSS is a multinational company operating businesses focusing on brand protection technology, blockchain security, direct marketing, healthcare, real estate and securitized digital assets. Document Security Systems is interested in SHRG because its focus on maximizing shareholder value through the acquisition and development of innovative companies, products, and technologies in the direct-selling industry dovetails nicely with DSS’s objectives. Sharing Services Global Corporation is a publicly traded company dedicated to maximizing shareholder value through the acquisition and development of innovative companies, products and technologies in the direct selling sector and other industries. The Sharing Services combined platform currently leverages the capabilities and expertise of various companies that market and sell products direct to the consumer through independent contractors. Sharing Services has two primary divisions: Elevacity(R) Holdings LLC, the parent company of Elevacity U.S. LLC, a health and wellness products company, and Elepreneurs Holdings LLC, the parent company of wholly owned subsidiary Elepreneurs U.S. LLC, a sales and marketing company based on utilization of independent contractor distributors who sell the Elevacity product line. For more information about the company, please visit www.SHRGInc.com, www.Elevacity.com or www.Elepreneur.com. NOTE TO INVESTORS: The latest news and updates relating to SHRG are available in the company’s newsroom at http://ibn.fm/SHRG

• Over one-third of hospitalized individuals are in danger of suffering neurological issues
• Traditional EEGs present various challenges, including cross-contamination
• NeuroCap(TM) makes EEGs more accessible, sanitary

Brain Scientific (OTCQB: BRSF), a commercial-stage healthcare company with two FDA-cleared products, provides next-gen solutions to the neurology market. Neurological care that reduces the opportunity of cross-contamination is critically needed in the effort to combat COVID-19.

According to the CDC’s national forecast data, the United States is predicted to report a new record of COVID-19 cases, anticipated to number between 1 million and 2.3 million new cases the week ending Jan. 2, 2021 (https://ibn.fm/NveF2). A recent Chinese study documented the neurological impacts of COVID-19 on 214 patients under treatment across three hospitals, noting that 36.4% of those patients presented neurological manifestations (https://ibn.fm/OOcAx), which often calls for electroencephalogram (“EEG”) testing. That number amounts to over one-third of hospitalized individuals. The need for EEG-trained technicians to administer the anticipated tests is quickly accelerating.

Every day scientists are learning more about COVID-19. More data is needed as the world works to flatten the curve and discover long-term effects and treatments. To better understand its impact on the brain, EEGs must become more accessible.

Traditional EEGs present various challenges. A trained technician is needed to fit, monitor and record the process. The test can take between 30 to 45 minutes to administer patient and requires close proximity, within eight inches, to the infected patient. The EEG, sensors and wires, if not fully sterilized, can also be a source of contamination.

The solution is a disposable EEG headset, Brain Scientific’s NeuroCap(TM). FDA cleared, this disposable pre-gelled EEG headset has 22 electrodes and 19 active EEG channels and is fully compatible with existing amplifiers. Because it is designed for a single use, it minimizes cross-contamination. The NeuroCap takes only five minutes to apply and can be administered by any clinical staff member; trained technicians are not required.

Knowledge-based decision making during this worldwide health pandemic is vital. Acquiring that knowledge in cost-effective ways that reduce the chance of cross-contamination is possible with BRSF’s innovative NeuroCap.

For more information, visit the company’s website at www.BrainScientific.com.

NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF

• Experts predict average price per kilowatt-hour for batteries will hit $101 by 2021, resulting in lower EV prices
• Battery prices would make an EV “cheaper than a gas car to buy,” observes “Car and Driver” article
• Mullen making strong strides toward production of several EV models

With the news from Bloomberg that the average price per kilowatt-hour for batteries is projected to hit $101 by 2021, it seems plausible that electric vehicles (“EVs”) may be comparable in price to gasoline-powered autos (https://ibn.fm/qofPF). That news paints a bright future for Net Element (NASDAQ: NETE), a global financial technology and value-added solutions group that has entered into a binding letter of intent to merge with privately held Mullen Technologies Inc., a Southern California-based electric vehicle company (https://ibn.fm/Fqg66). “In the showroom, electric vehicles still cost more than their gasoline counterparts,” a recent “Car and Driver” article noted. “Sure there are tax credits, the maintenance is far cheaper, and charging can be cheaper than refueling in some cases. But it’s that sticker price that keeps some shoppers away from the electric powertrain. . . . “Fortunately, it looks like the cost per kilowatt-hour is continuing to trend down, and according to a new report from energy research firm BloombergNEF (New Energy Finance), the market average should be $101 per kWh by 2023,” the article continued. “The $100-per-kWh price point is where experts expect the cost of EVs to match the prices of comparable gas-powered vehicles. If federal and state tax credits are still available at that time, it’s likely that they could make an EV cheaper than a gas car to buy.” As NETE moves closer to closing the merger with Mullen, the progress Mullen is making toward production of EVs bodes well for the company. In October, Mullen began turning its high-voltage battery R&D center in Monrovia, California, into a state-of-the-art pilot manufacturing facility for its line of fully electric SUVs (https://ibn.fm/nztgs). With construction scheduled to be completed by April 2021, the company anticipated its first MX-05 SUVs will roll off the production line by Q2 2022. With that in mind, Mullen begin taking pre-orders for its MX-05 SUV in October. The company is also taking pre-order for its Dragonfly K50, a pure electric, high-performance, limited-production sports car. In addition, the company has announced plans for its Mx-07 and MX-03 car models. Net Element Inc. is a global financial technology and value-added solutions group that supports electronic payments acceptance in an omni-channel environment spanning across point-of-sale, e-commerce and mobile devices. The company operates a payments-as-a-service transactional model and value-added services platform for small to medium enterprises in the U.S. and selected emerging markets. Earlier this year Net Element entered into a binding letter of intent to merge with Mullen Technologies in a stock-for-stock reverse merger. The proposed merger is currently pending the execution of a definitive agreement, shareholder vote and regulatory approval. For more information, visit the company’s website at www.NetElement.com. NOTE TO INVESTORS: The latest news and updates relating to NETE are available in the company’s newsroom at http://ibn.fm/NETE

• An estimated 7,000 to 9,000 people die every year in the U.S. due to medication errors
• A sizeable percentage of individuals dealing with medication mismanagement are older
• United Medical’s medication app offers 11 functionalities designed for health-care professionals, caregivers, students and family members

Each year, in the United States alone, an estimated 7,000 to 9,000 people die due to a medication error while hundreds of thousands of others experience adverse reactions or other complications related to medications, reports the National Center for Biotechnology Information (“NCBI”) (https://ibn.fm/cUBFl). United Medical Equipment Business Solutions Network is paying close attention to stats like these and, as a result, has created a powerful Medication Management app. “Close to 6,800 prescription medications and countless over-the-counter drugs are available in the United States,” reports the NCBI. “To further complicate a practitioner’s responsibility during patient care, there are thousands of health supplements, herbs, potions, and lotions used by the public regularly to treat their health problems. . . . . “The total cost of looking after patients with medication-associated errors exceeds $40 billion each year, with over 7 million patients affected,” the report continues. “In addition to the monetary cost, patients experience psychological and physical pain and suffering as a result of medication errors. Finally, a major consequence of medication errors is that it leads to decreased patients satisfaction and a growing lack of trust in the healthcare system.” A sizeable percentage of these individuals dealing with medication mismanagement are older. According to the American Public Health Association, people age 65 and older make up 12% of the U.S. population but account for 34% of all prescription medication use and 30% of all over-the-counter medication use (https://ibn.fm/t0keN). It is that demographic that United Medical is most interested in. The company is focused on providing reliable resources and solutions to fit the ever-changing needs of an aging population that includes seniors and veterans. United Medical’s Medication Management App is designed for health-care professionals, caregivers, students and family members who are providing direct and indirect patient care and education. The app features 11 different functionalities, including the following:

• Access to a medication/drug library for up-to-date information on medications and their indications, dosage, side effects, etc.
• Identification tools for medications that are not within their original containers
• Conversion systems for metric-U.S./Imperial quantities that includes weight, temperature, volume, and height
• Dosage converter for active medications/treatments whether in the hospital or at home
• Access to discount-rate CEUs for continuing education through Elite Healthcare
• IV (intravenous) and Y-site compatibility checker for nurses or medical personnel taking care of patients with IV access
• HIPAA Secure Messenger for messaging and discussions between health-care team members, educators and students, and even family members at home wishing to keep private information protected
• One-click HIPAA compliant video conferencing to speak with the UMEBSNI Health Resources or allow clinical educators to clinical students

United Medical offers initial downloads of its basic Medical Management App functionalities for both the iOS and Android platforms. The simple app is designed to help users prevent medication errors and make quick, well-informed — and even lifesaving — decisions. For more information, visit the company’s website at www.UnitedMedSolutions.com. To learn more about the company’s Medication Management app, visit www.MedicationManagement.app. NOTE TO INVESTORS: The latest news and updates relating to United Medical Equipment are available in the company’s newsroom at https://ibn.fm/UnitedMed

• Oregon is first state to permit supervised use of psilocybin, signaling shift in stigma
• CYBN entering phase 2 of clinical study of sublingual psilocybin for the potential treatment of MDD
• Newly discoverable data from psychedelic studies may potentially create entirely new marketplace of safe and effective drugs

Cybin (NEO: CYBN), a mushroom life sciences company, is working to become the first to bring a psilocybin drug to market targeting major depressive disorder (“MDD”). According to the National Institute of Mental Health, more than 18 million people in the United States — and 300 million people worldwide — experience major depression. Psilocybin has become a focus for academic institutions and companies whose clinical studies have been showing the effectiveness of psychedelics in mental health treatment. The stigmas around mushrooms are beginning to fade. Most cities have decriminalized psilocybin, but Oregon is the first to permit supervised use statewide (https://ibn.fm/e3Spg). The passing of Measure 109 does not legalize the everyday use of psychedelic mushrooms but instead enables the regulated use of the shrooms in a therapeutic setting. Over the next two years, regulatory details will be worked out, including the qualifications required for therapists to use the mushrooms. The Oregon Health Authority will provide oversight for the program, and therapy recipients will undergo pre-screening, a supervised therapy session and post-use evaluation. Psilocybin is still considered a Schedule 1 drug. Since 2018, the FDA has labeled psychedelic psilocybin a “breakthrough therapy” to treat MDD (https://ibn.fm/QCoge). This designation fast tracks the substance for clinical studies and for promising therapies that treat serious or life-threatening conditions and provide therapeutic benefits over available treatments (https://ibn.fm/REbvg). On Nov. 4, 2020, John Hopkins Medicine researchers published their latest psilocybin study in “JAMA Psychiatry.” According to Alan Davis, PhD and adjunct assistant professor of psychiatry and behavioral sciences at John Hopkins University School of Medicine, the results could be a game-changer (https://ibn.fm/EY74h). “The magnitude of the effect we saw was about four times larger than what clinical trials have shown for traditional antidepressants on the market,” said Davis. “Because most other depression treatments take weeks or months to work and may have undesirable effects, this could be a game changer if these findings hold up in future ‘gold-standard’ placebo-controlled clinical trials.” Cybind is at the forefront of companies conducting clinical trials and is entering phase 2 of its clinical study of sublingual psilocybin for the potential treatment of MDD at the beginning of 2021. The study’s objectives are to determine the appropriate dosing, evaluate clinical efficacy, and assess the safety and tolerability of psilocybin. The company seeks to partner with esteemed individuals and institutions leading the way in the research and development of pharmaceutical uses of psilocybin. This desire led to a partnership with the Toronto Centre for Psychedelic Science (“TCPS”) where some of the first academic research on micro dosing was published (https://ibn.fm/PI0t1). Both Cybin and TCPS have high standards for scientific rigor and transparency. CYBN believes that newly discoverable data from psychedelic studies can potentially create an entirely new marketplace of safe and effective drugs. For more information, visit the company’s website at www.Cybin.com. NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

• UUUU has signed three-year supply agreement with Chemours Company to obtain minimum 2,500 tons of rare earth and uranium-bearing natural monazite ore per year
• CEO notes company’s excitement about working with Chemours to help “reestablish U.S. rare earth production”
• Responsible production of REES, uranium from natural monazite ore is important complement to company’s existing programs

In what could be called a milestone moment in re-establishing a fully integrated REE supply chain in the United States, Energy Fuels (NYSE American: UUUU) (TSX: EFR) has announced a three-year supply agreement with the Chemours Company (NYSE: CC) (https://ibn.fm/XO0tG). The agreement calls for Energy Fuels to receive a minimum of 2,500 tons of natural monazite ore per year, one of the highest-grade rare earth element (“REE”) minerals in the world. Energy Fuels will process this monazite at its 100%-owned White Mesa Mill in Southeast Utah to produce a marketable mixed REE carbonate. “We are extremely excited about working with Chemours to help reestablish U.S. rare earth production,” said Energy Fuels president and CEO Mark S. Chalmers. “Chemours is a leader in the U.S. heavy mineral sands industry, and, together we are now taking an important first step in returning the REE supply chain back to the United States. We look forward to working with Chemours in the future to expand our mutual contributions to this important initiative. “This is a proud moment for Energy Fuels, as we deploy our unique capabilities to benefit both the environment and our shareholders,” he continued. “Energy Fuels already produces uranium, which is the fuel for clean, carbon-free nuclear energy. And we periodically produce vanadium, which is used in the production of steel, aerospace alloys, and advanced grid-scale batteries used to store renewable energy. The responsible production of rare earths and uranium from natural monazite sand ores is an important clean-technology addition to those programs.” Energy Fuels has long been an advocate for efforts made by the U.S. government to address the country’s overreliance on critical minerals needed for clean energy and advanced technologies from foreign sources and re-establish the rare earth and uranium supply chains with U.S. companies. “Energy Fuels stands ready to do our part in bringing uranium, vanadium and rare earth element processing and production back to the United States. We have led uranium industry efforts in Washington DC over the past three years to bring the issue of mineral supply chain security to the forefront, beginning with our Uranium Section 232 Petition, in which we asked the President to impose quotas on uranium imports,” said Chalmers earlier this year (https://ibn.fm/0II41). “Energy Fuels strongly supports the President’s declaration of a national emergency and invoking the Defense Production Act to free up the immediate government funding required to bring uranium production back to the United States and reduce our current dependency on imports from foreign adversaries, while also helping to fund U.S. vanadium and rare earth element production.” This supply agreement is tangible evidence of the the company’s active efforts to do all it can to bring production of these essential minerals back to the United States. This agreement should provide Energy Fuels with the natural monazite ore it needs to provide almost 10% of total current U.S. REE demand. In addition, UUUU is seeking additional natural monazite ore from other suppliers in order to increase its production. The company has the capacity to produce approximately 50% of U.S. REE demand in a mixed REE carbonate. Energy Fuels is also working with the U.S. Department of Energy to determine the possibility of processing other types of REE and uranium-bearing ores at the White Mesa Mill. Energy Fuels is a leading U.S.-based uranium mining company, supplying U₃O₈ to major nuclear utilities; the company also produces vanadium from certain of its projects, as market conditions warrant. Headquartered in Colorado, the company holds three of America’s key uranium production centers: the White Mesa Mill in Utah, the Nichols Ranch in-situ recovery (“ISR”) Project in Wyoming, and the Alta Mesa ISR Project in Texas. The White Mesa Mill is the only conventional uranium mill operating in the country today, has a licensed capacity of over 8 million pounds of U₃O₈ per year. The mill has the ability to produce vanadium when market conditions warrant and it was the largest U.S. supplier of high purity vanadium pentoxide in 2019. Energy Fuels is also completing final test-work for the production of REE carbonate from natural monazite ore, and expects to be in commercial rare earth production in 2021. The Nichols Ranch ISR Project is on standby and has a licensed capacity of 2 million pounds of U₃O₈ per year. The Alta Mesa ISR Project is also on standby and has a licensed capacity of 1.5 million pounds of U₃O₈ per year. For more information, visit the company’s website at www.EnergyFuels.com. NOTE TO INVESTORS: The latest news and updates relating to UUUU are available in the company’s newsroom at http://ibn.fm/UUUU

• Active hurricane season projected for 2021 according to recent report examining factors contributing to Atlantic basin hurricane activity
• Hurricanes cause extreme damage due to strong winds, flooding and storm surges that create large amounts of natural waste
• SGTM provides synergistic solutions to waste disposal problems created by hurricanes that benefit the environment

Not only did the 2020 hurricane season in the United States start early, but it broke records with so many storms that the National Hurricane Center used every name in its pre-determined list (https://ibn.fm/oaVg2). Meteorologists are now predicting that 2021 may be another active season that will likely result in serious repercussions on urban infrastructure and the environment (https://ibn.fm/TynAU). Sustainable Green Team (OTC: SGTM), a leading provider of environmentally-beneficial solutions for tree and storm waste disposal, will be on call to provide remediation efforts that divert natural storm waste from landfills and transform it into organic mulch products and playground surfacing material that benefit the environment.

Following a record 2020 hurricane season, 2021 is projected to be another active year, according to recently published research examining factors contributing to Atlantic basin hurricane activity. “Early indications are that 2021 could potentially be another active season,” said Phil Klotzbach a meteorologist from Colorado State University and specialist in Atlantic basin seasonal hurricane forecasts. “Right now, we have about a 50% chance of having an above-normal hurricane season.”

Hurricanes can cause extreme damage that results in physical, economic and environmental hardship. Strong winds can wield power so immense that they uproot trees and turn them into dangerous projectiles flying through the air. Accordingly, flooding can cause extreme damage to the foundations of buildings while destroying vehicles and vegetation. These two threats, however, pose moderate risks when compared to storm surges that cause the sea level to rapidly rise and then fall, decimating everything in their path as the hurricane makes its way onto land.

The consequences of these storms on people, infrastructure and the environment can be devasting, and the 2020 season was no exception. From its early start on May 14, 2020, the record-breaking season had so many storms that, for the second time in its history, the National Hurricane Center used every name in the pre-determined list and used the Greek alphabet for the remainder of the season.

SGTM played a significant role in the remediation efforts for many of these hurricanes, such as Hurricane Laura – an exceptionally violent storm that ravaged Louisiana and caused billions of dollars in damage (https://ibn.fm/DH632). Rather than allow the abundant tree and vegetative waste to add to the burden imposed on municipal landfills, SGTM acted quickly through its strategic partners to collect the waste and transport it to designated processing facilities for transformation into environmentally-beneficial products.

SGTM has grown and expanded throughout 2020 with numerous new contracts, strategic partnerships and operational investments that will enable the company to tackle whatever 2021 will bring its way. With a mission of protecting and serving the environment, SGTM is positioned to continue growing by offering services that transform serious problems into profits for the benefit of its clients and the communities the company serves.

To learn more about Sustainable Green Team Ltd., view the investor presentation at https://ibn.fm/6Kj3E.

NOTE TO INVESTORS: The latest news and updates relating to SGTM are available in the company’s newsroom at http://ibn.fm/SGTM

• The COVID-19 pandemic has sickened more than 78 million people worldwide, leading to the deaths of more than 1.7 million people
• The pandemic has hammered businesses as society has attempted to lessen human contact in order to limit the spread of the virus responsible for the illnesses, especially as a growing number of employees of the stressed companies have needed sick leave
• Autonomous Security Robot (“ASR”) developer Knightscope has enhanced its artificial intelligence-equipped sentries with elevated body temperature detection to help companies measure body temperatures of employees and visitors entering their facilities
• The feature will help client companies protect their employees from virus transmission on their premises, potentially reducing liability concerns in the process

As vaccines to combat the novel coronavirus begin to rollout across the country, Americans are acknowledging that it may take weeks or a number of months before a significant reduction of the pandemic’s threat takes place (https://ibn.fm/px2Cy). Autonomous security developer Knightscope has noted that one benefit of its robotic security teams patrolling select businesses and agencies across five time zones is that they are “immune and have been continuing to patrol across the country despite the pandemic” (https://ibn.fm/5356f). Now, the robots are also helping to provide a sense of COVID confidence by enabling elevated body temperature detection from wherever the sentries are located. “The Centers for Disease Control and Prevention indicates that a person with a temperature of 100.4 degrees or greater has a ‘fever,’ a symptom of COVID-19,” a recent Knightscope announcement states (https://ibn.fm/r5Z8W). “In an effort to help combat the spread of COVID-19, Knightscope developed a way for its clients to measure body temperatures of employees and visitors entering a facility.” The Pew Research Center reported in March that 24 percent of workers didn’t have access to any kind of paid sick leave prior to the pandemic, as noted in The Deseret News (https://ibn.fm/Z4f6T). Only 13 states currently require employers to offer paid sick leave. Fewer states passed temporary new measures in response to the coronavirus. But the need for sick workers to stay home if they’ve been infected means that businesses are not only under pressure as staffing levels become more critical, but also in dealing with the financial realities that their employees are wrestling with. Knightscope’s new solution ultimately protects companies and their employees from the threat of virus transmission in the workplace as well as from the traditional external safety issues surrounding potential crime, fire and property damage matters. “Our long-term ambition is to make the United States of America the safest country in the world,” the company’s website states. For more information, visit the company’s website at www.Knightscope.com. Visit www.Knightscope.com/invest for a summary of Knightscope as an investment, with a blue Instant Messaging button for direct contact with their CEO. DISCLAIMER: You should read the Offering Circular and risks related to this offering before investing. This Reg A+ offering is made available through StartEngine Primary, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. NOTE TO INVESTORS: The latest news and updates relating to Knightscope are available in the company’s newsroom at https://ibn.fm/Knight

• MustGrow study conducted by third-party lab reports 100% control of ravaging disease
• Fusarium wilt TR4 has devastated $25-billion global banana industry
• Next step in testing will evaluate patented biopesticide technology in additional lab and field settings

MustGrow Biologics (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0) has released potentially industry-changing results for its initial Colombia laboratory test evaluating the effect of its proprietary mustard-derived organic biopesticide formulation on the disease Fusarium wilt TR4. MustGrow’s study, which was conducted and reported via third-party laboratory CyberAgrot SAS in Colombia using Instituto Colombiano Agropecuario (“ICA”) official protocols, reports 100% control of the disease (https://ibn.fm/XhRSH). Sometimes called the Panama disease, Fusarium wilt TR4 has devastated the $25-billion global banana industry, reaching a point where the Colombian government actually declared a state of emergency. The lab results indicate a “unique feat — a feat MustGrow believes no other agri-science team has achieved”: controlling Fusarium wilt TR4 definitively. “This laboratory work will serve as a beachhead for more advanced testing to be used to achieve registration in Colombia and other leading banana producing countries,” MustGrow stated. In the announcement, MustGrow outlined the CyberAgrot study results. Carefully adhering to ICA official protocols, the test evaluated samples treated with MustGrow’s natural organic biopesticide as well as control samples that were left untreated. The study tested five different rates, and all data was measured after a five-day period. In all samples, MustGrow’s biopesticide showed 100% control of Fusarium wilt TR4. By contrast, all of the control samples showed Fusarium wilt TR4 still growing. “The CyberAgrot team is very pleased with the recent laboratory results of MustGrow’s mustard-derived product,” said industry expert and CyberAgrot general manager Alexander Chajin Robles. “This work further advances MustGrow towards our shared goal of combating the Panama disease, which has devastated the Banana Industry in Colombia and across the globe. Eliminating the disease is a national priority for the Colombian government, with the disease now affecting acres in many regions of Colombia.” The next step in testing will evaluate MustGrow’s patented biopesticide technology in the lab to refine the dose rates and then to see levels of control of Fusarium wilt TR4 in infected field settings. Fusarium wilt TR4 is the most destructive banana disease and is particularly harmful to Cavendish bananas, which are half of all bananas produced globally Once present, the disease remains viable in soil for decades and can result in complete crop loss; currently no effective treatments exist. “MustGrow’s product achieved 100% control of Fusarium wilt TR4, and we very much look forward to now begin field trials,” said Robles. “With further success, we will advance conversations with the Colombian Agriculture regulatory body as well as the Colombian Banana Association, accelerating MustGrow’s product as the only 100% organic solution to a growing crisis.  A very exciting opportunity.” MustGrow is an agriculture biotech company focused on providing natural, science-based biological solutions for high-value crops, including fruits and vegetables. MustGrow has designed and owns a U.S., EPA-approved natural solution that uses the mustard seed’s natural defense mechanism to protect plants from pests and diseases. More than 110 independent tests have been completed validating MustGrow’s safe and effective signature products. The product, in granule format, is EPA-approved across many key U.S. states and by Health Canada’s Pest Management Regulatory Agency (PMRA) as a biopesticide for high-value crops such as fruit and vegetables. MustGrow has now concentrated a liquid format, called TerraMG, which, with regulatory approval, could be applied through standard drip or spray equipment, improving functionality and performance features. For more information, visit the company’s website at www.MustGrow.ca. NOTE TO INVESTORS: The latest news and updates relating to MGROF are available in the company’s newsroom at https://ibn.fm/MGROF